Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ros-Arlanzón Pablo, Valverde-Mata Noelia, Almarcha-Menargues Maria-Luisa, Patiño Ángeles, Alonso-Cánovas Araceli, Pérez-Torre Paula, López-Sendón José Luis, Fanjul Samira, Kurtis Mónica M, Martínez-Castrillo Juan Carlos, Pareés Isabel
Аннотация
BACKGROUND: Oral levodopa is currently the most effective treatment for Parkinson’s disease (PD). However, many patients will suffer fluctuations as the disease progresses. CVT-301, an inhaled levodopa powder, has shown promise in clinical trials for managing OFF periods without severe side effects, yet real-world data are lacking. OBJECTIVES: To assess clinical effectiveness and tolerance of inhaled levodopa in PD patients. METHODS: observational study based on a retrospective chart review of consecutive PD patients treated with inhaled levodopa from April 2023 to May 2024. RESULTS: twenty-eight patients were included. Twenty (71.4%) reported improvement of OFF symptoms, with benefits appearing within 10 min in most patients. Adverse events were common. Only 2 (7.1%) discontinued treatment due to severe coughing. CONCLUSIONS: Inhaled levodopa offers rapid improvement in PD symptoms with acceptable tolerance. This real-world study underscores its potential benefit for PD-related fluctuations, widening on demand options for patients inadequately controlled by oral medications.